Sotio, A Clinical Stage Immuno-Oncology Company Owned By Ppf Group, Today Announced That The First Patient Has Been Dosed In Part B Of The Ongoing Phase 1/1B Study Of Il-15 Superagonist, So-C101, For The Treatment Of Patients With Advanced/Metastatic Solid Tumors. Part B Will Examine So-C101 In Combination With Pd-1 Inhibitor Pembrolizumab. The Trial Is Conducted In Partnership With Cytune Pharma.Early Results From The Ongoing Part A Of The Phase 1/1B Trial Investigating So-C101 Monotherapy Dose Escalation To Date Have Shown Encouraging Biological Activity, Activating Nk Cells And Cd8 T Cells In Various Solid Tumors. Part B Now Allows For The Pembrolizumab Combination Phase Of This Dose-Escalation Study To Progress. &Ldquo;Given Its Mechanism Of Action As A Pure Il-15 Receptor Agonist, So-C101 Has Promising Potential For A Combination Approach With Checkpoint Inhibitors. We Are Pleased To Have Reached This Important Milestone And Look Forward To Investigating So-C101 In Combination With Pembrolizumab,&Rdquo; Said Radek ŠPÍŠEk, Ph.D., Chief Executive Officer Of Sotio.Dr. David Bechard, President And Chief Operations Officer Of Cytune Pharma, Added, &Ldquo;We Are Thrilled To Be Advancing Our Collaboration With Sotio And Begin Enrolling Patients In This Important Phase Of The Clinical Trial. There Remains A High Unmet Medical Need To Evaluate Novel Potent Immunotherapies For Patients With Cancer.&Rdquo;The Ongoing Multicenter, Open-Label Phase 1/1B Study, Sc103 (Nct04234113), Is Evaluating The Safety And Preliminary Efficacy Of So-C101 As Monotherapy (Part A) And In Combination With Pembrolizumab (Part B) In Patients With Selected Relapsed/Refractory Advanced/Metastatic Solid Tumors.Cytune Pharma Is Responsible For The Clinical Development Of So-C101, Sotio Is A Sponsor Of The Phase 1 Clinical Trial. Both Companies Are Owned By Ppf Group.About Sotiosotio Is Shaping The Future Of Cancer Immunotherapies By Translating Compelling Science Into Patient Benefit. Sotio&Rsquo;S Robust Clinical Pipeline Includes A Differentiated Superagonist Of The Attractive Immuno-Oncology Target Il-15, A Platform To Streamline Personalized Active Immune Cell Therapies And A New Generation Of Potent And Stable Antibody-Drug Conjugates (Adcs). Sotio Is A Member Of The Ppf Group. Sotio Is A Registered Trademark Of Sotio A.S. In Selected Countries.
